Biotech News

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics (AQST)Aquestive TherapeuticsEarnings

Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approved Commercial preparations remain on track to support a potential U.S.

Related news

Aquestive Therapeutics

Oral Film Drug Delivery Company Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions. Anaphylm Anaphylm is a postage-stamp-sized sublingual film containing a prodrug of epinephrine for severe allergic reactions, including anaphylaxis. It dissolves without...

Recent company news

Stock data

Close
3.71 USD
Market cap
493.02M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States